CpG-siRNA Conjugates

CpG-siRNA Conjugates

BOC Sciences is committed to providing quality services related to CpG-siRNA conjugates. Professional and experienced scientists will work closely with you to help streamline and accelerate your research in both routine and custom services.

The advent of RNA interference (RNAi)-based therapeutic strategies has created a unique opportunity to silence any disease-related target gene. The main barriers to the clinical application of RNAi are targeted delivery of siRNA to the cell of interest and the sensitivity of the immune system to nucleic acid stimulation. However, immune cells themselves may be important therapeutic targets in cancer therapy. Ligands for intracellular receptors, such as TLR9, have been shown to serve as targeting components for cell-specific siRNA delivery. TLR9-positive cells recognize and internalize single-stranded oligodeoxyribonucleotides containing unmethylated CpG motifs (CpG ODNs). Conjugates of CpG ODNs with Dicer substrate siRNAs (CpG-siRNAs) are recognized by human and mouse TLR9 positive cells, without any transfection reagent, to target and silence genes in mouse TLR9+ immune cells, including dendritic cells (DCs), macrophages and B cells, in vitro and in vivo. Efficacy studies in mice have shown that CpG directly and/or immune-mediately targets various tumorigenic factors via siRNA, including antitumor-active STAT3, STAT5, RELA/P65, BCL2L1, or S1PR1. In summary, CpG-siRNA conjugates have several advantages:

  • Overcoming the limitations of small molecule drugs
  • No complex formulations or delivery vehicles are required
  • Enables dual targeting of cancer cells and immune cells, thereby improving efficacy

BOC Sciences provides a range of high-quality CpG-siRNA conjugates services, including:

Custom siRNA synthesis service

  • Selection of siRNA sequence
  • You can submit selected siRNA sequences or use our design tools to configure siRNA sequences.

  • Flexible siRNA synthesis scale
  • From mini-packs of 0.015 µmol scale to large orders.

  • Modification and labeling of siRNA
  • From conventional modifications to fluorescent/non-fluorescent labeling and even dual and multiple labeling services are available to suit your individual needs.

  • Strict quality control
  • Different purification methods according to individual requirements.

CpG ODN service

  • BOC Sciences provides a variety of CpG
    1. Native CPG that be functionalized with a linker and either a base or a modifier
    2. Universal CPG solid support for oligonucleotide synthesis
    3. Chemical modifications such as 3' end incorporation of unmodified U, puromycin, unmodified inosine, base-free spacer, locked nucleic acid T analogs, and locked nucleic acid A analogs
    4. CpG with labeling, including fluorescein, etc
  • CpG quality testing and stability analysis

CpG-siRNA conjugates service

  • Construction and purification of CpG-siRNA coupler molecules
  • Gene silencing effect evaluation analysis
  • Characterization of CpG-siRNA conjugates

Benefits of BOC Sciences' CpG-siRNA conjugates Service:

  • Flexible customization services- We synthesize according to your specific requirements.
  • High-quality products- Through strict quality control, our products are more stable, reproducible, and have a high siRNA loading efficiency.
  • Professional capabilities-We have experienced scientists, advanced analytical equipment and top-notch technology.
  • Complete transparency- You can check the progress of experiments and analysis results at any time.
  • More attentive service- 1 on 1 customer service, competitive price, and fast delivery.

Thank you for choosing BOC Sciences as your preferred CpG-siRNA conjugates service.

Our scientific team is ready to provide you with a flexible synthetic analysis service. If you have any special needs or questions, please feel free to contact us for support from our experienced experts.

References

  1. Hossain D; et al. TLR9-targeted sirna delivery in vivo. Methods in Molecular Biology. 2016, 1364: 183-96.
  2. Zhang Q; et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013, 121(8): 1304-1315.
* Only for research. Not suitable for any diagnostic or therapeutic use.
Online Inquiry
Verification code